Rifaximin in the treatment of hepatic encephalopathy

Maddalena Diana Iadevaia, Anna Del Prete, Claudia Cesaro, Laura Gaeta, Claudio Zulli, Carmelina LoguercioDepartment of Internistica Clinica e Sperimentale, F Magrassi e A Lanzara, Hepatogastroenterology Unit, Second University of Naples, Naples, ItalyAbstract: Hepatic encephalopathy is a challenging...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Iadevaia MD, Del Prete A, Cesaro C, Gaeta L, Zulli C, Loguercio C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/7e2e851629b54db6874a1d0ff5ab8e86
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e2e851629b54db6874a1d0ff5ab8e86
record_format	dspace
spelling	oai:doaj.org-article:7e2e851629b54db6874a1d0ff5ab8e862021-12-02T02:09:12ZRifaximin in the treatment of hepatic encephalopathy1179-1535https://doaj.org/article/7e2e851629b54db6874a1d0ff5ab8e862011-12-01T00:00:00Zhttp://www.dovepress.com/rifaximin-in-the-treatment-of-hepatic-encephalopathy-a8936https://doaj.org/toc/1179-1535Maddalena Diana Iadevaia, Anna Del Prete, Claudia Cesaro, Laura Gaeta, Claudio Zulli, Carmelina LoguercioDepartment of Internistica Clinica e Sperimentale, F Magrassi e A Lanzara, Hepatogastroenterology Unit, Second University of Naples, Naples, ItalyAbstract: Hepatic encephalopathy is a challenging complication in patients with advanced liver disease. It can be defined as a neuropsychiatric syndrome caused by portosystemic venous shunting, ranging from minimal to overt hepatic encephalopathy or coma. Its pathophysiology is still unclear, although increased levels of ammonia play a key role. Diagnosis of hepatic encephalopathy is currently based on specific tests evaluating the neuropsychiatric state of patients and their quality of life; the severity of hepatic encephalopathy is measured by the West Haven criteria. Treatment of hepatic encephalopathy consists of pharmacological and corrective measures, as well as nutritional interventions. Rifaximin received approval for the treatment of hepatic encephalopathy in 2010 because of its few side effects and pharmacological benefits. The aim of this work is to review the use and efficacy of rifaximin both in acute and long-term management of hepatic encephalopathy. Treatment of overt hepatic encephalopathy involves management of the acute episode as well as maintenance of remission in those patients who have previously experienced an episode, in order to improve their quality of life. The positive effect of rifaximin in reducing health care costs is also discussed.Keywords: acute hepatic encephalopathy, recurrent hepatic encephalopathy, rifaximin, lactulose, cost, health-related quality of lifeIadevaia MDDel Prete ACesaro CGaeta LZulli CLoguercio CDove Medical PressarticleDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2011, Iss default, Pp 109-117 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 Iadevaia MD Del Prete A Cesaro C Gaeta L Zulli C Loguercio C Rifaximin in the treatment of hepatic encephalopathy
description	Maddalena Diana Iadevaia, Anna Del Prete, Claudia Cesaro, Laura Gaeta, Claudio Zulli, Carmelina LoguercioDepartment of Internistica Clinica e Sperimentale, F Magrassi e A Lanzara, Hepatogastroenterology Unit, Second University of Naples, Naples, ItalyAbstract: Hepatic encephalopathy is a challenging complication in patients with advanced liver disease. It can be defined as a neuropsychiatric syndrome caused by portosystemic venous shunting, ranging from minimal to overt hepatic encephalopathy or coma. Its pathophysiology is still unclear, although increased levels of ammonia play a key role. Diagnosis of hepatic encephalopathy is currently based on specific tests evaluating the neuropsychiatric state of patients and their quality of life; the severity of hepatic encephalopathy is measured by the West Haven criteria. Treatment of hepatic encephalopathy consists of pharmacological and corrective measures, as well as nutritional interventions. Rifaximin received approval for the treatment of hepatic encephalopathy in 2010 because of its few side effects and pharmacological benefits. The aim of this work is to review the use and efficacy of rifaximin both in acute and long-term management of hepatic encephalopathy. Treatment of overt hepatic encephalopathy involves management of the acute episode as well as maintenance of remission in those patients who have previously experienced an episode, in order to improve their quality of life. The positive effect of rifaximin in reducing health care costs is also discussed.Keywords: acute hepatic encephalopathy, recurrent hepatic encephalopathy, rifaximin, lactulose, cost, health-related quality of life
format	article
author	Iadevaia MD Del Prete A Cesaro C Gaeta L Zulli C Loguercio C
author_facet	Iadevaia MD Del Prete A Cesaro C Gaeta L Zulli C Loguercio C
author_sort	Iadevaia MD
title	Rifaximin in the treatment of hepatic encephalopathy
title_short	Rifaximin in the treatment of hepatic encephalopathy
title_full	Rifaximin in the treatment of hepatic encephalopathy
title_fullStr	Rifaximin in the treatment of hepatic encephalopathy
title_full_unstemmed	Rifaximin in the treatment of hepatic encephalopathy
title_sort	rifaximin in the treatment of hepatic encephalopathy
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/7e2e851629b54db6874a1d0ff5ab8e86
work_keys_str_mv	AT iadevaiamd rifaximininthetreatmentofhepaticencephalopathy AT delpretea rifaximininthetreatmentofhepaticencephalopathy AT cesaroc rifaximininthetreatmentofhepaticencephalopathy AT gaetal rifaximininthetreatmentofhepaticencephalopathy AT zullic rifaximininthetreatmentofhepaticencephalopathy AT loguercioc rifaximininthetreatmentofhepaticencephalopathy
_version_	1718402657529364480

Rifaximin in the treatment of hepatic encephalopathy

Ejemplares similares